FDA Approves Generic GLP-1 Medicine, Liraglutide, (a Victoza Generic), For Diabetes Treatment

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 27, 2024.

By Denise Maher HealthDay Reporter

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for people living with Type 2 diabetes.

Liraglutide, the generic for Victoza, is similar to semaglutide, the active ingredient in the popular weight-loss drug Ozempic.

The FDA supports the development of generic drugs, such as GLP-1s, by funding research and informing industry through guidance, Dr. Iilun Murphy, director of the FDA’s Office of Generic Drugs, said.

“Generic drugs provide additional treatment options which are generally more affordable for patients,” she said in a statement released Dec. 23, 2024.

“Today’s approval underscores the FDA’s continued commitment to advancing patient access to safe, effective and high-quality generic drug products.”

Last month, the agency approved the first generic version in this class of medications with the green lighting of a generic version of Byetta (exenatide).

Experts hope the new approvals will help prevent shortages triggered by demand for injectable weight loss and type 2 diabetes drugs, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

Liraglutide is expected to expand access for people managing type 2 diabetes, which affects more than 38 million Americans, according to federal health data.

Type 2 diabetes is a chronic condition that occurs when the body does not use insulin well and cannot keep blood sugar at normal levels. It is usually diagnosed in adults, but has been increasingly diagnosed in children and teens.

Liraglutide improves blood sugar levels by creating similar effects in the body as GLP-1 in the pancreas, which is often found in insufficient levels in those with type 2 diabetes.

The prescribing information for the generic version includes a warning about the increased risk of thyroid C-cell tumors.

For this reason, patients who have had, or have family members who have ever had medullary thyroid carcinoma should not use liraglutide, nor should those who have an endocrine system condition called multiple endocrine neoplasia syndrome type 2.

The most common side effects reported in the clinical trials for liraglutide injection include nausea, diarrhea, vomiting, decreased appetite, dyspepsia and constipation.

Sources

  • FDA, news release, Dec. 23, 2024
  • CNN

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-12-27 12:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords